CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently, and Regeneron Pharmaceuticals, a leading biotechnology company invents, develops and commercializes life-transforming medicines for people with serious diseases, both jointly announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX
